Autosomal recessive polycystic kidney disease (ARPKD) is a rare genetic disease that leads to renal failure in 70% of patients. Not all cases have a known cause, resulting in a lack of effective treatment and misdiagnosis.
Errors in the gene PKHD1 were once known as the main cause but it has not explained all occurrence, as some patients have been found to have normal versions of PKDH1.
Now a research team from the University of Queensland, led by Carol Wicking, have confirmed a link between the disease and another gene, DZIP1L.
DZIPL1 was initially linked to the disease using whole exome sequencing. This identified it in the genome of ARPKD patients.
Using laboratory-based models, Wicking and colleagues have demonstrated that mutations in DZIP1L can lead to altered functioning of cilia, the hair-like structures that cover most mammalian cells. Cilia are vital for kidney cell functioning.
“This gene makes a protein that acts at the base of the cilium, which, when faulty, causes a domino effect that leads to problems in cilia and, in turn, a malfunctioning kidney, ” Wicking explains. “ARPKD has a more complex cause than originally thought.”
The discovery should benefit sufferers by providing comfort and certainty in their diagnosis, and by also allowing them to build support networks with other suffers, says Nicole Mills, the executive director of Rare Voices Australia, an organisation representing the interests of people with rare diseases.
Ariella Heffernan-Marks in a Melbourne-based science writer.
Read science facts, not fiction...
There’s never been a more important time to explain the facts, cherish evidence-based knowledge and to showcase the latest scientific, technological and engineering breakthroughs. Cosmos is published by The Royal Institution of Australia, a charity dedicated to connecting people with the world of science. Financial contributions, however big or small, help us provide access to trusted science information at a time when the world needs it most. Please support us by making a donation or purchasing a subscription today.